Monitor the progress of the Phase 3 VERSATILE-003 trial and upcoming catalysts, including PFS data readout in 2Q 2026 and final data readout in 1H 2027. The positive clinical data could lead to increased investor interest and potential partnerships.
PDSB drugs
PDSB drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 27 $0.9300entry
- T+1 · 7mo ago +16.13%α +16.61% · $1.08
- T+5 · 7mo ago +7.53%α +7.13% · $1.00
- T+20 · 6mo ago +18.28%α +13.32% · $1.10
- T+60 · 4mo ago −23.06%α −27.84% · $0.7155
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
PDS Biotechnology updated its corporate presentation deck, which includes positive clinical trial data for its lead compound PDS0101 in combination with pembrolizumab for HPV16-positive recurrent/metastatic head and neck cancer. The presentation highlights a median overall survival of 39.3 months and a 77.4% disease control rate, which is significantly better than the 12-18 month benchmark with current standard of care.
Key Facts
- PDS Biotechnology updated its corporate presentation deck on April 24, 2026
- The presentation highlights clinical data for PDS0101 in combination with pembrolizumab for HPV16-positive recurrent/metastatic head and neck cancer
- The trial showed a median overall survival of 39.3 months, compared to a 12-18 month benchmark with current standard of care
- The disease control rate was 77.4%
- The company has a Phase 3 pivotal trial (VERSATILE-003) underway with FDA alignment on the primary endpoint for accelerated approval
- The presentation also highlights the company's global IP portfolio with PDS0101 exclusivity through 2041/2042
Financial Impact
The positive clinical data could significantly increase the company's valuation, especially if the Phase 3 trial is successful. The total addressable market in the US is estimated at $1.0B for HPV16+ HNSCC.
Risk Factors
- The company is a clinical-stage biotech with no approved products, so it is highly dependent on the success of its clinical trials
- The company may need additional financing to fund its operations, which could lead to dilution
- The company's ability to protect its intellectual property is a key risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-016684 |
| Document: ef20071434_8k.htm | 0001140361-26-016684 |
| Document: 0001140361-26-016684-index-headers.html | 0001140361-26-016684 |
| Document: 0001140361-26-016684-index.html | 0001140361-26-016684 |
| Document: 0001140361-26-016684.txt | 0001140361-26-016684 |
Track record
28 reports on PDSB
6 of 13 bullish or bearish reports moved the stock their way by T+20. Best: +71.95% at T+20 after the Jul 22, 2026 report. 10 of 13 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 4/10 Entry $0.8726 Now $0.9240 +5.89% settles Dec 14
- Nov 12, 20264d ago SC 13D/A Neutral 4/10 Entry $0.9800 Now $0.9240 −5.71% settles Dec 11
- Nov 10, 20266d ago 8-K Neutral 4/10 Entry $1.03 Now $0.9240 −10.29% settles Dec 9
- Oct 20, 202627d ago 3 Neutral 2/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
- Oct 20, 202627d ago 8-K Neutral 4/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
- Oct 20, 202627d ago 8-K Neutral 3/10 Entry $0.9605 Now $0.9240 −3.80% settles Nov 17
- Oct 14, 20264w ago S-3 Bearish 7/10 Entry $1.30 to $0.9800 Now $0.9240 +28.92% ▲ +24.62% +22.71% vs SPY
- Oct 6, 20265w ago 8-K Neutral 3/10 Entry $1.05 to $1.41 Now $0.9240 −11.58% ▲ +34.93% +38.10% vs SPY
- Sep 22, 20267w ago 8-K Bullish 6/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
- Sep 22, 20267w ago Press Release Bullish 7/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers